MedTrace Logo

To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

NCT05331014 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2024-03-15

No results posted yet for this study

Summary

A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.

Conditions

Interventions

DRUG

LivaloVA

For 8 weeks(PO, QD)

DRUG

LivaloV

For 8 weeks(PO, QD)

DRUG

VA

For 8 weeks(PO, QD)

Sponsors & Collaborators

Principal Investigators

  • Gyurok Han, CI · Gangdong Sacred Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2022-11-08
Completion
2022-11-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05331014 on ClinicalTrials.gov